Amgen Launches Eylea Biosimilar Pavblu at Discount; GSK Invests $800M in Manufacturing
核心洞察
Amgen has launched Pavblu, its biosimilar to Regeneron's Eylea, at a 10% discount, pricing it at $1,665 per dose, potentially muting its market impact.
GSK is investing $800 million to expand its manufacturing site in Pennsylvania, focusing on sterile liquid vaccines and medicines production.
Roche and Dyno Therapeutics (搜索) are collaborating to advance AAV gene therapy vectors for neurological diseases (搜索), with Dyno receiving $50 million upfront.
Amgen has initiated the launch of its biosimilar to Regeneron's Eylea (aflibercept), branded as Pavblu, setting the price at $1,665 per dose. This represents a 10% discount compared to Eylea's current wholesale cost. The launch proceeds despite ongoing legal challenges from Regeneron, creating a degree of risk for Amgen.
Pavblu's Market Entry
RBC analyst Brian Abrahams suggests that the modest price reduction may result in a less pronounced market impact than initially anticipated by Amgen investors. The FDA has already approved four other biosimilars for Eylea, suggesting that further price erosion is possible as more competitors enter the market. Eylea is used to treat macular degeneration, diabetic retinopathy and other retinal diseases.
GSK's Manufacturing Expansion
GSK is making a substantial investment of $800 million to expand its manufacturing facility in Marietta, Pennsylvania. This investment will support the production of sterile liquid vaccines and medicines, with the new facilities expected to be operational by the end of 2028. The expansion also includes a drug substance facility and a pilot plant for manufacturing clinical trial medicines, slated to begin operations by the end of 2027.
Roche and Dyno Therapeutics Collaboration
Roche has entered into a second research collaboration with Dyno Therapeutics (搜索), focusing on the development of adeno-associated virus (AAV) gene therapy vectors for neurological diseases (搜索). Dyno will design improved vectors to deliver genetic medicines to specific targets within the nervous system. Roche will handle the testing and commercialization of any resulting therapies. Dyno will receive $50 million upfront, research payments, potential royalties, and could receive over $1 billion upon achieving certain milestones.
AbbVie and Gideon Richter Partner on Neuropsychiatric Targets
AbbVie (搜索) and Gideon Richter (搜索) are collaborating to discover new targets for treating neuropsychiatric conditions (搜索). The companies will share research and development costs. Richter will receive $25 million upfront, with potential milestone and royalty payments. AbbVie will gain worldwide rights to commercialize resulting programs, except in Richter's traditional markets, such as Europe and Russia.
Marinus Pharmaceuticals' Trial Results
Marinus Pharmaceuticals announced that a Phase 3 study of its seizure (搜索) drug ganaxolone in people with epilepsy (搜索) related to tuberous sclerosis complex (搜索) did not meet the trial's goal. The company will lay off staff, cut costs and consider strategic alternatives.